Navigation Links
OmniSonics Appoints J. Daniel Cole Chairman of the Board
Date:9/24/2007

WILMINGTON, Mass., Sept. 24 /PRNewswire/ -- OmniSonics Medical Technologies, Inc., a leading developer of advanced medical devices for occlusive vascular disease, today announced the appointment of J. Daniel Cole as the company's new Chairman of the Board.

Mr. Cole is a founding partner with Spray Venture Partners, a venture capital firm that focuses exclusively on emerging healthcare technology companies. He brings twenty years of medical device operational experience, having served on the boards of 10 companies, two of which he started. Prior to joining Spray, Mr. Cole served as senior vice president and group president of Boston Scientific Corporation's (BSC) vascular business, a $1.2 billion group, and was also responsible for BSC's international operations. Prior to BSC, he was president and chief iperating officer of SCIMED Life Systems before the company's merger with Boston Scientific. He also held a variety of executive and general management positions at Baxter Healthcare. He currently serves on the Board of Directors of Acorn Cardiovascular, Tryton Medical, Direct Flow Medical, and Tremont Medical, and is actively involved in Kolis Scientific, PneumRx, and Thoratec Laboratories.

"We are thrilled to have Dan Cole as our new Chairman of the Board for OmniSonics," said Richard Ganz, president and CEO, OmniSonics Medical Technologies. "Over the last few years, we have been actively building a world-class team with in-depth experience in product development and commercialization. Dan's experience and leadership will be a major asset as we launch our products for vascular occlusive disease and build a word-class commercial enterprise."

"This is an exciting time to join the OmniSonics team," said J. Daniel Cole, Chairman of the Board and partner at Spray Venture Partners. "The company has assembled a management team with over 80 cumulative years of experience in medical devices and commercial operations. They have developed breakthrough technology for treating vascular occlusive disease - technology that has the chance to have a major impact on a serious health issue. The company is ready for the transition from R&D to commercialization, and I'm looking forward to being a part of that transition."

About OmniSonics Medical Technologies, Inc.

OmniSonics Medical Technologies, Inc., based in Wilmington, MA, is a venture-backed medical device company focused on developing breakthrough products for the treatment of vascular occlusive disease. The Company plans to introduce products based on its patented OmniWave(TM) Technology, the first technology capable of delivering low-power acoustic energy around the active length of a small diameter wire in a diseased blood vessel. OmniWave Technology is designed to have broad applications in vascular occlusive conditions. Clearance for use in peripheral vascular disease is expected in 2007. Additional clinical trials are planned for other indications.

Contact: Judith Rossi

978-657-9980 X502

jrossi@omnisonics.com


'/>"/>
SOURCE OmniSonics Medical Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... Information Management ... Web product. The upgrade represents a completely new technical foundation and is so ... offer a responsive design interface, significantly increased speed for search results, a streamlined layout ...
(Date:2/8/2016)... Feb. 8, 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that its new website has ... resource–user-centric, story-driven, knowledge-based and mobile-friendly. Visit the new ... ... ... "The goal was to reimagine ...
(Date:2/5/2016)... , Feb. 5, 2016  In the pharmaceutical ... for a host of launch activities including the identification ... this launch activity is especially high in the oncology ... Best Practices and the Role of Medical Affairs ... companies focused on oncology therapies find better ways to ...
(Date:2/4/2016)... - New FDA action date of July 22, ... July 22, 2016   --> - ...   - Lifitegrast has the potential to be the ... signs and symptoms of dry eye disease in adults ... product approved in the U.S. in the past decade indicated for the treatment of ...
Breaking Biology Technology:
(Date:1/20/2016)... 20, 2016  Synaptics Incorporated (NASDAQ: SYNA ... today announced sampling of S1423, its newest ClearPad ... small screen applications including smartwatches, fitness trackers, and ... and rectangular shapes, as well as thick and ... moisture on screen, while wearing gloves, and supports ...
(Date:1/15/2016)... , Jan. 15, 2016 Recent publicized ... small to find new ways to ensure data security ... iOS and Android that ties ... biometrics, transforming it into a hardware authorization token. Customer ... swipe their fingerprint on their KodeKey enabled device to ...
(Date:1/13/2016)... , January 13, 2016 /PRNewswire/ ... announced the addition of the  "India ... Estimation & Forecast (2015-2020)"  report ... http://www.researchandmarkets.com/research/7h6hnn/india_biometrics ) has announced the addition ... Identification Market - Estimation & Forecast ...
Breaking Biology News(10 mins):